Treatment of otitis media with cefuroxime axetil.
Cefuroxime axetil and cefaclor were compared for efficacy in the treatment of acute otitis media with effusion. Sixty-four pediatric outpatients had tympanocentesis for culture, and then were randomized to a ten-day course of treatment with cefuroxime axetil or cefaclor. Streptococcus pneumoniae and Haemophilus influenzae were isolated from 25 (39%) and 23 (36%) patients, respectively. Treatment was beneficial in 26 (90%) of the patients who received cefuroxime axetil, and in 16 (76%) of the cefaclor-treated patients. Treatment failed in five (24%) of the cefaclor-treated patients, and in only three (10%) patients who received cefuroxime axetil. Haemophilus influenzae was the initial causative pathogen in a disproportionate number of treatment failures. This study demonstrates the efficacy of cefuroxime axetil in the treatment of otitis media.
D000208:Acute Disease; D002433:Cefaclor / Q000008:administration & dosage / Q000627:therapeutic use; D002444:Cefuroxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002511:Cephalosporins; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010034:Otitis Media with Effusion / Q000150:complications / Q000188:drug therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011355:Prodrugs / Q000008:administration & dosage* / Q000009:adverse effects; D011897:Random Allocation
D002511:Cephalosporins; D004364:Pharmaceutical Preparations; D011355:Prodrugs; D002433:Cefaclor; D002444:Cefuroxime; C040738:cefuroxime axetil